In a phase 3 clinical trial of adjuvant dabrafenib and trametinib (BRAF and MEK inhibitors, respectively) in patients with resected stage III melanoma, the prognostic value of the five-gene IFN-γ expression signature and the TMB was investigated [60]. Here, MAP2K7 is linked to melanoma.